Peptide Library / Weight & Metabolic
Semaglutide
Also known as: The molecule behind Ozempic / Wegovy
The peptide that changed the conversation — the original blockbuster GLP-1 agonist, with the deepest human trial record of any compound on this site.
| Typical research dose | 0.25 mg/week to start; titrate every 4 weeks (approved range 0.25–2.4 mg/week) |
|---|---|
| Frequency | 1× weekly |
| Route | Subcutaneous injection |
| Cycle length | Ongoing with titration; not a short cycle |
Figures reflect protocols commonly reported in the research community — not a prescription or a recommendation.
What it is
Semaglutide is a GLP-1 receptor agonist — a modified version of a gut hormone that regulates appetite and blood sugar. It's the active molecule in Ozempic (diabetes), Wegovy (weight), and Rybelsus (oral), which makes it the single most recognized peptide on earth. It has years of approved real-world use and enormous trial datasets — in research-chemical form it is the same molecule outside the pharmaceutical supply chain, which is why third-party testing matters doubly here.
What the research looks at
- Weight — STEP trials: ~15% average body-weight loss at 68 weeks at 2.4 mg.
- Blood sugar — the original indication; strong A1c reduction.
- Cardiovascular — approved CV-risk-reduction indication (SELECT trial showed ~20% reduction in major cardiac events in overweight adults).
- Everything else — kidney disease, liver fat, addiction-behavior research; the GLP-1 literature is the fastest-growing in medicine.
How protocols are commonly structured
The pharmaceutical titration is the template: 0.25 mg once weekly for 4 weeks, then 0.5 → 1.0 → 1.7 → 2.4 mg, stepping up no faster than monthly and holding at the lowest effective dose. Slower is smoother — nearly all the GI misery in this class comes from rushing the ladder. Protein and resistance training are the standard companions to protect muscle during loss.
Compared to its siblings: tirzepatide trials showed larger average loss, and retatrutide larger still (in phase 2) — semaglutide's edge is the longest approved track record and the gentlest introduction to the class.
One standing rule for the whole GLP-1 class: anyone with a personal or family history of medullary thyroid cancer sits this category out, and anyone on diabetes medication coordinates with their prescriber first.
Reconstitution & storage
Lyophilized powder; bacteriostatic-water reconstitution (calculator). Weekly mg dosing; refrigerate after mixing.
Research protocols, not a prescription — talk to a physician before touching anything.